Limitations and lessons in the use of X-ray structural information in drug design

Teaser The use of X-ray crystal structure models continues to provide a strong stimulus to drug discovery, through the direct visualisation of ligand–receptor interactions. There is sometimes a limited appreciation of the uncertainties introduced during the process of deriving an atomic model from the experimentally observed electron density. Here, some of these uncertainties are highlighted with recent examples from the literature, together with snippets of advice for the medicinal chemist embarking on using X-ray crystal structure information in a drug discovery programme.

[1]  R. Nussinov,et al.  How different are structurally flexible and rigid binding sites? Sequence and structural features discriminating proteins that do and do not undergo conformational change upon ligand binding. , 2007, Journal of molecular biology.

[2]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[3]  Mitchell R Seim,et al.  Exploring the active site of phenylethanolamine N-methyltransferase with 1,2,3,4-tetrahydrobenz[h]isoquinoline inhibitors. , 2007, Bioorganic & medicinal chemistry.

[4]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[5]  Terry K. Smith,et al.  Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids. , 2006, Journal of molecular biology.

[6]  M. Schumacher,et al.  Crystal structures of SarA, a pleiotropic regulator of virulence genes in S. aureus , 2001, Nature.

[7]  Woody Sherman,et al.  Use of an Induced Fit Receptor Structure in Virtual Screening , 2006, Chemical biology & drug design.

[8]  Pravin Kumar Gadakar,et al.  Pose Prediction Accuracy in Docking Studies and Enrichment of Actives in the Active Site of GSK-3β , 2007, J. Chem. Inf. Model..

[9]  Stephen Hanessian,et al.  A method for induced-fit docking, scoring, and ranking of flexible ligands. Application to peptidic and pseudopeptidic beta-secretase (BACE 1) inhibitors. , 2006, Journal of medicinal chemistry.

[10]  T. Poulos,et al.  Structure-based design and synthesis of N(omega)-nitro-L-arginine-containing peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. Displacement of the heme structural water. , 2007, Journal of medicinal chemistry.

[11]  Raymond C. Stevens,et al.  Structural Basis for BABIM Inhibition of Botulinum Neurotoxin Type B Protease , 2000 .

[12]  Robin Taylor,et al.  A new test set for validating predictions of protein–ligand interaction , 2002, Proteins.

[13]  Gerhard Klebe,et al.  Thermodynamic inhibition profile of a cyclopentyl and a cyclohexyl derivative towards thrombin: the same but for different reasons. , 2007, Angewandte Chemie.

[14]  Heather A Carlson,et al.  Exploring experimental sources of multiple protein conformations in structure-based drug design. , 2007, Journal of the American Chemical Society.

[15]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[16]  T A Jones,et al.  Electron-density map interpretation. , 1997, Methods in enzymology.

[17]  R. Dawson,et al.  Structure of a bacterial multidrug ABC transporter , 2006, Nature.

[18]  G J Kleywegt,et al.  Validation of protein crystal structures. , 2000, Acta crystallographica. Section D, Biological crystallography.

[19]  R. Stevens,et al.  Structural Basis for BABIM Inhibition of Botulinum Neurotoxin Type B Protease [J. Am. Chem. Soc. 2000, 122, 11268−11269]. , 2002 .

[20]  Akiko Itai,et al.  Effective handling of induced‐fit motion in flexible docking , 2006, Proteins.

[21]  Jean M. Severin,et al.  Crystal structures of human adenosine kinase inhibitor complexes reveal two distinct binding modes. , 2006, Journal of Medicinal Chemistry.

[22]  D. E. Clark What has computer-aided molecular design ever done for drug discovery? , 2006, Expert opinion on drug discovery.

[23]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[24]  Gerhard Klebe,et al.  Evidence for a novel binding site conformer of aldose reductase in ligand-bound state. , 2007, Journal of molecular biology.

[25]  Haruki Nakamura,et al.  Reply to: Building meaningful models of glycoproteins , 2007, Nature Structural &Molecular Biology.

[26]  Haruki Nakamura,et al.  Announcing the worldwide Protein Data Bank , 2003, Nature Structural Biology.

[27]  Gerard J Kleywegt,et al.  Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. , 2003, Angewandte Chemie.

[28]  Gisbert Schneider,et al.  Structure-based virtual screening of FGFR inhibitors: cross-decoys and induced-fit effect. , 2007, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[29]  J. Gready,et al.  Combining docking and molecular dynamic simulations in drug design , 2006, Medicinal research reviews.

[30]  Yingfang Liu,et al.  Structural and function analyses of the global regulatory protein SarA from Staphylococcus aureus , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[32]  U. Krengel,et al.  Novel binding site identified in a hybrid between cholera toxin and heat-labile enterotoxin: 1.9 A crystal structure reveals the details. , 2007, Structure.

[33]  Gerard J Kleywegt,et al.  Experimental Data for Structure Papers , 2007, Science.

[34]  Terry K. Smith,et al.  Reevaluation of the PPAR-β/δ Ligand Binding Domain Model Reveals Why It Exhibits the Activated Form , 2006 .

[35]  Retraction Kiehntopf,et al.  Retraction , 1997, Concurr. Comput. Pract. Exp..

[36]  Claus-Wilhelm von der Lieth,et al.  pdb-care (PDB CArbohydrate REsidue check): a program to support annotation of complex carbohydrate structures in PDB files , 2004, BMC Bioinformatics.

[37]  Eric F. Johnson,et al.  The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.

[38]  Maria A. Schumacher,et al.  correction: Crystal structures of SarA, a pleiotropic regulator of virulence genes in S. aureus , 2001, Nature.

[39]  P. Ross,et al.  Thermodynamics of protein association reactions: forces contributing to stability. , 1981, Biochemistry.

[40]  T. Jones,et al.  Between objectivity and subjectivity , 1990, Nature.

[41]  Gerard J Kleywegt,et al.  Pound-wise but penny-foolish: How well do micromolecules fare in macromolecular refinement? , 2003, Structure.

[42]  Gerard J. Kleywegt,et al.  Retrieval and validation of structural information , 2005 .

[43]  Axel T. Brunger,et al.  Substrate recognition strategy for botulinum neurotoxin serotype A , 2004, Nature.

[44]  Chuan Yi Tang,et al.  A 2.|E|-Bit Distributed Algorithm for the Directed Euler Trail Problem , 1993, Inf. Process. Lett..

[45]  C. Enroth,et al.  The crystal structure of phenol hydroxylase in complex with FAD and phenol provides evidence for a concerted conformational change in the enzyme and its cofactor during catalysis. , 1998, Structure.

[46]  Greg Miller,et al.  A Scientist's Nightmare: Software Problem Leads to Five Retractions , 2006, Science.

[47]  T. Sjögren,et al.  Structural basis for ligand promiscuity in cytochrome P450 3A4 , 2006, Proceedings of the National Academy of Sciences.

[48]  C. Enroth High-resolution structure of phenol hydroxylase and correction of sequence errors. , 2003, Acta crystallographica. Section D, Biological crystallography.

[49]  David I. Stuart,et al.  Building meaningful models of glycoproteins , 2007, Nature Structural &Molecular Biology.

[50]  Clifford A Goudey,et al.  Aquaculture in Offshore Zones , 2006, Science.

[51]  Raymond C. Stevens,et al.  Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Å resolution , 2000, Nature Structural Biology.

[52]  Debasis Mallik,et al.  A 2.13 A structure of E. coli dihydrofolate reductase bound to a novel competitive inhibitor reveals a new binding surface involving the M20 loop region. , 2006, Journal of medicinal chemistry.

[53]  E. Brown,et al.  High throughput screening identifies novel inhibitors of Escherichia coli dihydrofolate reductase that are competitive with dihydrofolate. , 2003, Bioorganic & medicinal chemistry letters.

[54]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[55]  G. Gao,et al.  The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[56]  I Kolossváry,et al.  Fully flexible low-mode docking: application to induced fit in HIV integrase. , 2001, Journal of the American Chemical Society.

[57]  S. Teague Implications of protein flexibility for drug discovery , 2003, Nature Reviews Drug Discovery.

[58]  Jonas Boström,et al.  Reproducing the conformations of protein-bound ligands: A critical evaluation of several popular conformational searching tools , 2001, J. Comput. Aided Mol. Des..

[59]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[60]  T. Blundell,et al.  pH-tuneable binding of 2′-phospho-ADP-ribose to ketopantoate reductase: a structural and calorimetric study , 2007, Acta crystallographica. Section D, Biological crystallography.

[61]  S. Homans,et al.  Water, water everywhere--except where it matters? , 2007, Drug discovery today.

[62]  Gerard J. Kleywegt,et al.  Crystallographic refinement of ligand complexes , 2006, Acta crystallographica. Section D, Biological crystallography.

[63]  J. Tainer,et al.  2-aminopyridines as highly selective inducible nitric oxide synthase inhibitors. Differential binding modes dependent on nitrogen substitution. , 2004, Journal of medicinal chemistry.

[64]  Brian W Matthews,et al.  Five retracted structure reports: Inverted or incorrect? , 2007, Protein science : a publication of the Protein Society.

[65]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[66]  Eric F. Johnson,et al.  The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.

[67]  D. M. F. Aalten,et al.  PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules , 1996, J. Comput. Aided Mol. Des..

[68]  Alice Stanton,et al.  Structure-based design of aliskiren, a novel orally effective renin inhibitor. , 2003, Biochemical and biophysical research communications.

[69]  P. Goodford A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[70]  Frank E. Blaney,et al.  Crystal Structure of Human Cytochrome P450 2D6* , 2005, Journal of Biological Chemistry.

[71]  A. Davis,et al.  Hydrogen Bonding, Hydrophobic Interactions, and Failure of the Rigid Receptor Hypothesis. , 1999, Angewandte Chemie.

[72]  D. Ballou,et al.  Studies of the mechanism of phenol hydroxylase: mutants Tyr289Phe, Asp54Asn, and Arg281Met. , 2001, Biochemistry.

[73]  A. W. Schüttelkopf,et al.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.

[74]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.

[75]  Bernhard Rupp,et al.  Questions about the structure of the botulinum neurotoxin B light chain in complex with a target peptide , 2001, Nature Structural Biology.

[76]  Martin Frank,et al.  Data mining the protein data bank: automatic detection and assignment of carbohydrate structures. , 2004, Carbohydrate research.

[77]  Zbigniew Dauter,et al.  What happens when the signs of anomalous differences or the handedness of substructure are inverted? , 2007, Acta crystallographica. Section D, Biological crystallography.

[78]  J. Lehmann,et al.  Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. , 2000, Molecular cell.

[79]  G. Klebe,et al.  Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions. , 2006, Journal of molecular biology.

[80]  Yingfang Liu,et al.  Crystal structure of the SarR protein from Staphylococcus aureus , 2001, Proceedings of the National Academy of Sciences of the United States of America.